Sustained Vision Improvement in RP11 Patients

• PYC is developing an investigational drug candidate (known as VP-001) with the potential to become the first approved treatment option for patients with the blinding eye disease Retinitis Pigmentosa type 11 (RP11)1 • Patients receiving VP-001 in the ongoing Phase 1/2 clinical trials demonstrate sustained improvement in vision in the treated eye up to 18 months after initiation of treatment2 • Th